Sangel Capital

company

About

one of the earliest globally operating professional biomedical venture capital institutions in China

Highlights

Details

Operating Status
Active
Investor Type
Venture Capital

Sangel Capital as one of the earliest globally operating professional biomedical venture capital institutions was established in China in 2010, focusing on life science and technology, and having leading professional advantages and rich project resources in the biomedical investment industry.
Sangel Capital has offices in Shenzhen, Beijing, Suzhou, and Chicago. We bring together a group of investment and advisory teams composed of industry experts, scientists, and investors in the field of life technology to manage and operate a series of RMB and USD funds.

Investments

Number of Investments
Number of Lead Investments
2
0
Sangel Capital has made 2 investments. Their most recent investment was on Oct 23, 2020, when Sirnaomics raised $105M.
Date Company Name
Round Money Raised Industry Lead Investor
Oct 23, 2020 Sirnaomics
Series D $105M Biopharma
Oct 19, 2020 3D Medicines
Private Equity(PE) ¥1.50B Biopharma